Table 2.

Results of CEC, VEGFR2+-BMD progenitor, VEGF, and sVEGFR2 levels for 45 patients with localized or metastatic pediatric solid malignancies

PatientAge/SexLocalized disease (n = 23)Initial diagnosis/relapsed disease (n = 34/11)CEC/mL% VEGFR2+-BMD*, , , §(absolute value/mL)CD34+/mLVEGF (ng/mL)sVEGFR2 (ng/mL)
CNS tumor
    P11.3/MGlioneuronal tumorI160.5 (15)3,23084110,313
    P22.7/MBrain stem pilocytic astrocytomaI00.7 (24)3,3309887,977
    P32.7/MLow grade glioma (ventricles)I410.3 (4)1,4055329,170
    P49.4/FBrain stem gliomaI61.7 (ND)ND09,492
    P511.5/MAtypical teratoid rhabdoid tumorI174.1 (ND)ND609,781
    P66.3/MMedulloblastomaI140.1 (3)2,3667211,942
    P79.5/FMedulloblastomaI00.7 (135)19,9572712,708
    P818/FMedulloblastomaI72.3 (ND)ND287,784
Sarcoma
    P94.7/MRhabdomyosarcomaI520.3 (6)1,97509,045
    P1013/MRhabdomyosarcomaI60.7 (16)2,550527,401
    P119/FUndifferentiated sarcoma (liver)I00.7 (4)51415211,304
    P129.3/FSynovialosarcomaR126.2 (78)1,3604413,164
    P1317/FPrimitive neuroectodermal tumorI32.7 (16)61006,988
    P1414.3/MEwing's tumorI150 (0)ND011,566
    P1516.5/MEwing's tumorI00.4 (ND)ND2810,392
    P1622.5/MEwing's tumorI30.1 (4)3,9102110,541
Lymphoma
    P175.3/FHodgkin's disease (I)I72.4 (30)1,4951510,352
    P1816.8/MBurkitt lymphoma (I)I00.8 (8)1,030328,431
Other
    P191/FHepatoblastomaI70.4 (5)1,02872610,958
    P201.4/MHepatoblastomaI400.2 (2)1,3453010,284
    P211/MNephroblastoma (bilateral)I40.2 (3)1,7732419,467
    P225.8/MNephroblastomaI40.7 (19)2,6081249,526
    P235.7/MNeuroblastoma (NMYC+)I118.5 (76)1,0201107,602
Patient
Age
Sex
Metastatic disease (n = 22)
Initial diagnosis/relapsed disease (n = 34/11)
Metastatic site
CEC/mL
% VEGFR2+-BMD*§(absolute value/mL)
CD34+/mL
VEGF (ng/mL)
sVEGFR2 (ng/mL)
Sarcoma
    P2411MOsteosarcomaIBone1221.5 (55)3,67610312,598
    P2514.9MOsteosarcomaILung, bone387.3 (23)3807911,216
    P2615MOsteosarcomaILung1526.4 (71)1,190959,817
    P2715FEwing's tumorILung306.1 (18)37007,309
    P2810MAlveolar RhabdomyosarcomaRBM159.4 (16)2955911,209
    P2917MOsteosarcomaRLung402.8 (46)1,78099,931
    P3018.5MOsteosarcomaRLung810.3 (33)41046,813
    P3119.2MOsteosarcomaRLung40.7 (4)645287,759
    P3219.9MOsteosarcomaRLung74.3 (ND)ND157,976
Lymphoma
    P333.5MAnaplasic lymphoma (III)IPleural582.1 (ND)ND379,439
    P3411.5FAnaplasic lymphoma (III)I22.9 (60)2,575021,113
    P3514.3MHodgkin's disease (IV Bb)ILung, bone50.8 (ND)ND24010,064
CNS tumor
    P364FGlioblastomaILeptomeningeal01.2 (ND)ND7212,295
    P3720.7MMedulloblastomaRBrain, BM22.5 (63)2,595011,761
Other
    P382.7MNeuroblastoma (NMYC-)IBM, bone60.9 (ND)ND6910,133
    P393FNeuroblastoma (NMYC-)IBM, liver40.4 (15)4,0685456,601
    P403MNeuroblastoma (NMYC-)ILymph nodes62.5 (ND)ND52111,067
    P415MNeuroblastoma (NMYC-)IBM, bone180.6 (88)14,81298811,070
    P427FNeuroblastoma (NMYC-)RBM948.6 (50)5821348,470
    P4325MNeuroblastoma (NMYC-)RBM, liver545.2 (60)1,161768,695
    P4410MHepatoblastomaREndovascular07.9 (89)1,285307,695
    P4521MNephroblastoma (2nd relapse)RPancreas07.7 (ND)ND307,939
  • Abbreviations: BM, bone marrow; I, initial diagnosis; R, relapsed disease; ND, not determined.

  • * VEGFR2+-BMD progenitor cells were defined as CD45dimCD34+VEGFR2(KDR)+7AAD events.

  • P values: all 45 patients, localized versus metastatic disease, P < 0.001.

  • All 45 patients, initial versus relapsed disease, P < 0.0001.

  • § Patients at initial diagnosis (n = 34), localized versus metastatic disease, P < 0.02.

  • CD34+ cell counts determined as CD45dim/−CD34+ events.

  • Patients with lymphoma were distinguished according to Ann Arbor staging as having localized (stage I or II) or metastatic disease (stage III or IV).